Celiac disease in type 1 diabetes mellitus

Maria Erminia Camarca1, Enza Mozzillo1,2, Rosa Nugnes1,3, Eugenio Zito1, Mariateresa Falco1, Valentina Fattorusso1, Sara Mobilia1, Pietro Buono1, Giuliana Valerio2, Riccardo Troncone1 and Adriana Franzese1*

Abstract
Celiac Disease (CD) occurs in patients with Type 1 Diabetes (T1D) ranging the prevalence of 4.4-11.1% versus 0.5% of the general population. The mechanism of association of these two diseases involves a shared genetic background: HLA genotype DR3-DQ2 and DR4-DQ8 are strongly associated with T1D, DR3-DQ2 with CD. The classical severe presentation of CD rarely occurs in T1D patients, but more often patients have few/mild symptoms of CD or are completely asymptomatic (silent CD). In fact diagnosis of CD is regularly performed by means of the screening in T1D patients. The effects of gluten-free diet (GFD) on the growth and T1D metabolic control in CD/T1D patient are controversial. Regarding of the GFD composition, there is a debate on the higher glycaemic index of gluten-free foods respect to gluten-containing foods; furthermore GFD could be poorer of fibers and richer of fat. The adherence to GFD by children with CD-T1D has been reported generally below 50%, lower respect to the 73% of CD patients, a lower compliance being more frequent among asymptomatic patients. The more severe problems of GFD adherence usually occur during adolescence when in GFD non compliant subjects the lowest quality of life is reported. A psychological and educational support should be provided for these patients.

Keywords: Diabetes, Celiac disease, Genetic background, HLA, Dietetic compliance, Glycaemic index, Gluten free diet, Quality of life

Introduction
Type 1 Diabetes Mellitus (T1D) is frequently associated to other autoimmune conditions. These conditions can severely affect clinical management of the disease, especially in paediatric age.

The most frequent are autoimmune thyroid disease (AIT), celiac disease (CD), Addison’s disease (AD) and vitiligo. These diseases are associated with organ-specific autoantibodies: AIT with thyroid peroxidase (TPO) and thyroglobulin autoantibodies (TG), CD with endomyrial (EMA) and transglutaminase (TTG) autoantibodies, and AD with adrenal autoantibodies. Using these autoantibodies, organ-specific autoimmunity may be often detected before the development of clinical disease, in order to prevent significant morbidity related to unrecognized disease [1]. These diseases are very often clustered in the same individual and a shared genetic background probably explains this association [2].

Genetics
The majority of autoimmune endocrine diseases, including T1D, are inherited as complex genetic traits. Multiple genetic and environmental factors interact with each other to confer susceptibility to these disorders. Genetic risk factors associated with T1D, ATD, CD and AD include HLA genes and non-HLA genes.

HLA DR4 and DR3 are strongly associated with T1D and approximately 30-50% of patients are DR3/DR4 heterozygotes. The DR3/DR4 genotype confers the highest diabetes risk with a synergic mode of action, followed by DR4 and DR3 homozygosity, respectively. The HLA-DQ (particularly DQ2 and DQ8) locus has been found to be the most important determinant of diabetes susceptibility. Approximately 90% of individuals with T1D have either DQ2 or DQ8, compared to 40% of the general population [3]. So, the highest-risk human leukocyte antigen (HLA) genotype for T1D is DR3-DQ2, DR4-DQ8.

DR3-DQ2 shows a strong association with CD; homozygosity for DR3-DQ2 in a population with T1D carries a 33% risk for the presence of TTG autoantibodies [4].

* Correspondence: franzese@unina.it
1Department of Paediatrics, “Federico II” University, Naples, Italy
Full list of author information is available at the end of the article

© 2012 Camarca et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Non-HLA genes are also involved in the predisposition to T1D and other autoimmune diseases, such as MIC-A, PTPN22, CTLA-4 [1].

**Epidemiology**

Traditional studies, both in children and adults, have shown that CD occurs in patients with T1D with a prevalence that varies from 4.4 to 11.1% compared with 0.5% of the general population (Table 1 for references from) [5-14]. The mean age at diagnosis of classical CD is commonly around 2-3 years, while the mean age at diagnosis of T1D is 7-8 years. The age at onset of T1D is younger in patients with the double disease than in those with only T1D [15]. The risk of CD is negatively and independently associated with age at onset of diabetes, with an higher risk being seen in children age < 4 years than in those age > 9 years [16]. In patients with T1D, diabetes is usually diagnosed first, CD precedes diabetes onset only in 10-25% [16,17], while generally CD diagnosis in T1D patients occurs, trough the screening performed at diabetes onset, in 70-80% of patients with a median age > 8 years. Some authors hypothesized that in genetically susceptible patients one disease could predispose to another. Particularly, it has been suggested that untreated (latent or silent) CD could be an immunological trigger and induce diabetes and/or thyroid disorders due to gluten as a driving antigen [18].

**CD clinical symptoms**

The most severe CD-related symptoms are generally related to gastrointestinal malabsorption and include malnutrition, failure to thrive, diarrhea, anorexia, constipation, vomiting, abdominal distension, and pain. These features are more common in children younger than three years of age. Non-gastrointestinal symptoms of CD include short stature, pubertal delay, fatigue, vitamin deficiencies, and iron deficiency anemia and are more commonly observed in older children. The gastrointestinal presentation of CD rarely occurs in T1D patients (< 10%), but many patients with CD and T1D are either asymptomatic (silent CD) or present only mild symptoms [17,20,22]. Furthermore, the wide spectrum of CD include also subjects with positive celiac-related antibodies without diagnostic small-bowel mucosal villous atrophy. This condition is defined as potential celiac disease (pot-CD) [23-25]. Data from the majority of childhood diabetes care centers in Italy showed that prevalence of pot-CD patients in this population (higher in females than males) is 12.2%, while the prevalence of pot-CD in the CD control population is 8.4% and only few of them present CD-related symptoms [26].

**CD-screening**

Diagnosis of CD is regularly due to screening protocols which are widely recommended and performed. Actually diagnosis is commonly performed by means of TTG IgA (confirmed by EMA) or TTG-IgG if IgA-deficiency is present. Screening has to performed at followed times: 1) at the time of diabetes onset, 2) yearly in the first 4 years of follow up, 3) each 2 years in the successive 6 years of follow up [27,28]. In the presence of CD-related antibodies positivity it is mandatory to perform bowel biopsy to confirm diagnosis of CD, even if in very recent guide-lines of ESPGHAN Society [29] it is proposed that in evident CD-cases it is possible to avoid biopsy (4 main criteria).

| Reference                | Country       | N.    | Age (yr) | Screening          | Prevalence (%) |
|-------------------------|---------------|-------|----------|--------------------|----------------|
| Cerutti et al. 2004     | Italy         | 4322  | 11.8 ± 4 | AGA + EMA          | 6.8            |
| Contreas et al. 2004    | North Italy   | 357   | Children | EMA                | 7              |
| Sanchez et al. 2005     | Germany       | 281   | Children | AGA + EMA          | 6.4            |
| Araujo et al. 2006      | Brasil        | 354   | Children | TG                 | 10.5           |
| Goh et al. 2007         | UK            | 113   | Children | EMA + TG + AGA     | 4.4            |
| Larsson et al. 2008     | Sweden        | 300   | < 20     | EMA                | 10             |
| Karavanaki et al. 2009  | Greece        | 144   | 12.3 ± 46| TG                 | 4.8            |
| Djuric et al. 2010      | Serbia        | 121   | Mean 108 | TG                 | 5.79           |
| Bhadada et al. 2011     | India         | 189   | 10.81 ± 7.3 | TG             | 11.1          |
| Gabriel S et al. 2011   | Romania       | 119   | 11 ± 4   | TG                 | 9.2            |
CD-treatment
GFD should be proposed actually only in patients with mucosal atrophy. In patients with overt CD, identifying and treating CD with gluten free diet (GFD) surely confer benefit in reducing/resolving malabsorption, infertility, osteoporosis, poor nutrition, impaired growth and long-term malignancy risks and mortality rates [30-32]. Similarly, children with T1D and symptomatic CD benefit from GFD [33] and also metabolic control of diabetes could be ameliorated [34].

On the contrary, in symptom-free patients weight gain and bone mineral density (BMD) changes have been non-univocally described as benefit [35-37]. The different viewpoints highlight the need of a prolonged follow up in patients affected by T1D and asymptomatic CD to clarify the role of GFD. Some authors argument that GFD in asymptomatic CD-T1D patients should be opportune proposed but not excessively stressed [38,39].

Finally, no definite consensus exists among experts about to treat by GFD pot-CD patients, in whom recently it has been suggested that GFD could be a benefit [40]. Concerning to the natural history of patients whit pot-CD, a recent study shows that 30% of these patients develops overt CD in a three years follow-up and underlines the necessity of re-testing [41]. However no data are available about the follow-up of patients with T1D and pot-CD.

Surprisingly, intestinal inflammation has been described also in T1D patients without CD-related antibodies and structurally normal intestinal mucosa [42]. According to this, our group has observed a gluten-related inflammation either in rectal either in small bowel mucosa of children with T1D [43,44]. It can be speculated that gluten could be an optimal candidate to stimulate an abnormal innate immune reaction in intestinal mucosa due to its pro-inflammatory characteristics. It remains a crucial issue to establish if the extended intestinal inflammation in T1D is gluten-dependent and whether it precedes the occurrence of the disease.

Bone impairment: a hidden threat
In patients with only T1D it is possible to demonstrate impairment of bone metabolism and structure, specially in relationship with duration and/or poor control of diabetes [45]. Furthermore CD also have been underlined as cause of bone impairment. Clinical observation indicates that clustering of three autoimmune diseases (T1D, CD and generally thyroiditis) significantly increases the occurrence of osteopenia (37.5%). It is possible that bone impairment might be considered not only a complication due to endocrine or nutritional mechanisms, but also a consequence of an immunoregulatory imbalance [46]. In fact osteoclasts are now considered as the innate immune cells in the bone, since they are able to produce and respond to cytokines and chemokines. Bone remodelling involves complex interactions between osteoclasts and other cells in bone microenvironment (marrow stromal cells, osteoblasts, macrophages, T-lymphocytes and marrow cells) [47]. Several cytokines, like the cytokine receptor activator of NFkB ligand (RANKL) and the macrophage colony stimulating factor (M-CSF), can promote osteoclast formation and activity. Also osteoprotegerin (OPG), a circulating secretory glycoprotein, could have a role in bone remodelling in children with T1D because it could promote differentiation, fusion, survival, activation and apoptosis of the osteoblasts. Alterations or abnormalities of the RANKL/OPG system have been implicated in different metabolic bone diseases characterized by increased osteoclast differentiation and activation, and by enhanced bone resorption [48].

In patients affected by both T1D and CD, the risk of developing osteopenia is also influenced by the compliance to GFD. In fact, osteopenia occurs more frequently in patients with diabetes and CD with poor compliance to GFD [49]. Recent observations indeed indicated an imbalance of cytokines relevant to bone metabolism in untreated celiac patients’ sera and the direct effect of these sera on in vitro bone cell activity. In particular the RANKL/osteoprotegerin (OPG) ratio was increased in patients not on gluten-free diet [46].

In conclusion osteopenia seems to be a new occult problem in CD patients, in T1D patients and in patients with two or three immunological diseases, depending also on GFD.

GFD composition
Diet is a fundamental part of the treatment in both T1D and CD. However GFD composition could present some problems for diabetic people (Table 2).

The glycemic index (GI) provides an indirect measure of the ability of a food to raise blood glucose. GI is retained a direct index of absorption of carbohydrates, being: “the area under curve of blood glucose after eating a food containing a determined quantity of carbohydrate”. White bread (GI = 100) is usually compared as reference value. In normal subjects ingestion of foods with high GI leads to a rapid blood glucose increase causing a marked insulin response. In diabetes, diet containing food with high GI is

| Reference       | HbA1c    | BMI gain | Heigh velocity |
|-----------------|----------|----------|----------------|
| Westman et al.  | unchanged| Unchanged| unchanged       |
| Saukkonen et al.| unchanged| Increased| unchanged       |
| Amin et al.     | reduced  | Increased| unchanged       |
| Saadah et al.   | unchanged| Increased| unchanged       |
| Valletta et al. | unchanged| Unchanged| unchanged       |
considered inopportune because in condition of insulin deficiency (T1D) or insulin inefficacy (type 2 diabetes) the normal insulin response is not obtainable; traditionally the common diet of the diabetes people consists principally in foods with low GI. In 2002 American Society for Clinical Nutrition published an international table, revised by an older published of the sixties, which shows the GI of most common foods, evaluated in comparison to glucose and to white bread [50], (Table 3) where gluten-free products have higher GI-foods than similar products gluten containing. In Paker’s study [51] six types of gluten-free foods are compared with white bread containing gluten. These foods were eaten from 11 adult patients with type 2 diabetes and blood glucose was measured after eating. Results showed no difference about GI among gluten-free foods and those containing gluten. On the contrary, Berti et al. show a higher blood glucose curve for gluten-free foods, although with similar insulin curves and with contradictory results between in vivo and in vitro analysis. (Table 4), [52]). Specific studies both in healthy patients and in type 1 and type 2 diabetic patients should be necessary, particularly in pediatric age.

In addition, gluten-free foods are prepared using corn flour, rice and wheat, where the percentage of fiber, carbohydrate, fats and micronutrients isn’t completely known. Scarce contrasting data generally describe in gluten free foods composition few proteins, more fat and few fibers than gluten containing foods. (from SCHAR website and Ministry of Agriculture website, Tables 5 and 6). In addition in the review of Kupper [53] GFD seems to can be the cause of a multiple nutrients deficiency, especially of vitamin B, vitamin D, calcium, magnesium, iron, zinc, but sources of his information are not well documented. Finally Berti et al. [52] reported higher amount of fats in gluten-free bread than those with gluten, but the same amount of fibers (Table 7).

Compliance/adherence to GFD and quality of life (QOL)

Adherence to GFD among T1D-CD patients, in our experience, is generally good in patients who experienced clear clinical symptoms of CD, but is scarce among patients with few symptoms or asymptomatic. In Table 8 a summary of the data of literature is presented, but authors did not specify whether patients had experienced symptoms; data of our group are also presented [36]. In contrast with T1D population, dietary compliance in CD patients (without T1D), seems to be higher: approximately 73% of patients followed the diet strictly [54]. Probably for a patient with T1D, already engaged in coping day by day a complex chronic disease, the addition of a second “limiting” condition, is a remarkable discomfort [55]. Consequently, in the case of double diagnosis (T1D + CD), it is very difficult to manage patients who did not experienced CD symptoms.

Studies on the compliance/adherence to GFD in non diabetic people showed that, in relation to the social life, children usually have a better compliance to GFD than adults [56]. In a follow-up of 10 years in the Netherlands conducted on children from 2 to 4 years who received CD diagnosis by screening, authors described a general improvement of health without deterioration in QOL [57]. In concordance Kolsteren showed that the QOL of celiac children is quite similar to that of other children [58]. Usually the difficulty with the diet occurs when the patient became adolescent, because she/he needs to feel equal to peers, especially when she/he decides to go out to eat and more acutely she/he feels limits imposed by GFD. According to Wagner et al. [59] celiac adolescents non compliant with GFD reported a lower general QOL, more physical problems, a higher burden of illness, more family troubles, and more problems in leisure time than adolescents who are compliant with GFD. No differences between compliant patients with CD and adolescents without any chronic condition were found in all QOL aspects.

It is also important remark that the balance between GFD adherence and daily life is difficult to achieve for the child/adolescent who is also affected by an other chronic disease such as T1D. The need to coordinate insulin therapy with proper nutrition and a healthy lifestyle, in order to maintain adequate metabolic control, is already a considerable effort for the young T1D-patient and families [60]. Rebellions are frequent especially in adolescents, who are already feeling diabetes as very “invasive” for all the aspects of daily life and who receive a further “restriction” constituted by the GFD. Consequently there it could be the risk, especially if this proposal is not properly, to elicit a response of complete rebellion which will endanger not only the adherence to the GFD [36,54,55], but also the entire management of T1D, causing a sharp deterioration of general compliance and increasing the risk of severe acute complications (recurrent ketoacidosis, unawareness

### Table 3 GI of some gluten-free foods, compared to glucose and white bread

| Food                   | Gl glucose 100 | Gl bread 100 |
|------------------------|----------------|--------------|
| Gluten-free multigrain bread | 79 ± 13       | 113          |
| Gluten-free white bread   | 76 ± 5        | 108 ± 7      |
| Gluten-free fiber enriched bread | 73 ± 4     | 104 ± 5      |

### Table 4 GI of gluten-free foods evaluated in vivo, compared to white bread (= 100)

| Food                   |   |
|------------------------|---|
| Gluten-free bread      | 230|
| Gluten-free pasta      | 255|
| Quinoa                 | 186|
hypoglycemia). In addition it is possible to think that this further limit could be a trigger also of eating disorders in adolescent patients, being eating disorders not rare and previously reported in diabetes. Regarding QOL, Sud et al. [61] in children with T1D-CD showed that the double diagnosis appears to have a minimal impact on QOL, even if patients’ parents reported a very important difficulty on management. It is interesting that not significant differences in QOL were observed with regard to age at CD diagnosis and duration, or on the basis of adherence with a GFD. Furthermore parents of T1D-CD children did express greater concern about their child’s social functioning.

### Conclusions

Prevalence of CD among children with T1D is significantly higher than in non diabetic children. In a large proportion CD is asymptomatic or characterized by modest/atypical symptoms. Periodic screening of CD auto-antibodies is mandatory. CD diagnosis requires the biopsy confirmation and it is necessary to prescribe GFD in the presence of mucosa impairment. Concerning the clinical benefits of GFD in T1D-CD patients, data are contrasting, except in severely symptomatic patients. Osteopenia seems to be a new occult problem in CD patients, in T1D patients and in patients with two or three immunological diseases, depending also on GFD.

### Table 5 Nutritional composition of gluten free and containing gluten foods

| Products                        | PROT (g) | CHO (g) | SUGARS (g) | FATS (g) | FIBER (g) | KCALS |
|---------------------------------|----------|---------|------------|----------|-----------|-------|
| Flour 00                        | 11       | 77.3    | 1.7        | 0.7      | 2.2       | 340   |
| Gluten-free flour               | 1.2      | 86.3    | 1.5        | 0.8      | 45        | 357   |
| Crackers containing gluten      | 9.4      | 80.1    | 2.5        | 10       | 2.8       | 428   |
| Gluten-free crackers            | 5.2      | 74.7    | 5.2        | 12.7     | 2.9       | 434   |
| Cereal flakes containing gluten | 6.6      | 87.4    | 10.4       | 0.8      | 3.8       | 361   |
| Gluten-free cereals             | 8        | 80      | 5.3        | 16       | 5         | 361   |
| Rusks containing gluten         | 11.3     | 82.3    | 2.2        | 8.2      | 3.5       | 408   |
| Gluten-free rusks               | 4.8      | 82.9    | 5.4        | 1.4      | 3.6       | 425   |
| Pasta containing gluten         | 10.9     | 79.1    | 4.2        | 2.5      | 2.7       | 353   |
| Gluten-free pasta               | 9        | 73.7    | 0.4        | 7.9      | 2.2       | 353   |
| Biscuits                        | 6.6      | 84.8    | 18.5       | 14.3     | 2.6       | 416   |
| Gluten-free biscuits            | 2.7      | 79.9    | 16.1       | 0.8      | 0.8       | 459   |

### Table 6 Portion size, macronutrient and micronutrient composition of test meal.

|                      | White bread | GF biscuits | GF white Unsliced bread | GF fibre Sliced bread | GF white Sliced bread | GF fibre Unsliced bread | GF pasta |
|----------------------|-------------|-------------|-------------------------|-----------------------|-----------------------|-------------------------|----------|
| Serving (g)          | 107         | 73          | 101                     | 119                   | 101                   | 119                     | 64       |
| Energy (kcal)        | 232         | 335         | 221                     | 225                   | 221                   | 236                     | 230      |
| Protein (g)          | 8.1         | 2.55        | 3.03                    | 3.57                  | 3.03                  | 3.57                    | 5.05     |
| Carbohydrate (g)     | 50          | 50          | 50                      | 50                    | 50                    | 50                      | 50       |
| (g sugars)           | 3.21        | 17.5        | 4.54                    | 5.36                  | 4.50                  | 5.35                    | 0.61     |
| Fat (g)              | 1.39        | 13.87       | 1.01                    | 1.19                  | 1.01                  | 2.38                    | 1.02     |
| (g saturated)        | 0.32        | 4.38        | 0.50                    | 0.60                  | 0.50                  | 1.19                    | 0.32     |
| Fibre (g)            | 1.61        | 2.92        | 1.01                    | 5.95                  | 1.01                  | 7.7                     | 0.96     |
| Sodium (g)           | 0.56        | 0.37        | 0.51                    | 0.47                  | 0.51                  | 0.35                    | 0.05     |

### Table 7 Weight of meal and nutrient composition of 50 g available carbohydrate portions of the foods studied as served.

| Tests foods | Weight of meal (g) | Protein (g) | Water (g) | Carbohydrate (g) | Fat (g) | Total dietary fibers (g) |
|-------------|-------------------|-------------|-----------|------------------|---------|--------------------------|
| Bread       | 100               | 9.4         | 31.4      | 50               | 3.6     | 2.8                      |
| GF Bread    | 125               | 5.7         | 38.5      | 50               | 9.7     | 3.9                      |
| GF Pasta    | 156               | 3.2         | 61.2      | 50               | 0.6     | 2.1                      |
| Quinoa      | 320               | 3.4         | 75.9      | 50               | 2.0     | 2.8                      |

GF = gluten-free
It is unclear whether GFD composition could present any disadvantages regarding of glycemic index, fibers, percentage of fat and micro-nutrients. Data are not universal on this point.

Communication of the need of GFD in patients with T1D-CD is particularly delicate, especially in adolescents where it is possible to trigger rebellion behaviors. The coexistence of these two diseases in the same patient requires care by clinicians and probably a specific psychological approach.

**Abbreviations**

AIT: Autoimmune thyroid disease; AD: Addison’s disease; BMD: Bone mineral density; CD: Celiac disease; EMA: Endomysial autoantibodies; GFD: Gluten-free diet; HbA1C: Glycated hemoglobin; HLA: Human leukocyte antigen; pot-CD: Potential celiac disease; QOL: Quality of life; T1D: Type 1 diabetes; TG: Thyroglobulin autoantibodies; TPO: Peroxidase autoantibodies; TTG: Transglutaminase autoantibodies

**Authors details**

1Department of Paediatrics, “Federico II” University, Naples, Italy. 2School of Movement Sciences (DISIST)- Parthenope University, Naples, Italy. 3Department of Cellular and Molecular Pathology “L. Califano”, “Federico II” University, Naples, Italy.

**Authors’ contributions**

MEC (MD), EM (MD), PB (MD): have been involved in drafting the manuscript, except “Composition diet”, “Compliance/adherence to GFD and quality of life” and “Genetics”. EZ (Psy. D): has been involved in drafting “Compliance/adherence to GFD and quality of life”. MF (MD), VF(MD): acquisition of data. SM (Dietitian): has been involved in drafting the manuscript. AF (MD): conception and design of the manuscript. EZ (Psy. D): has been involved in drafting “Genetics”. GV (MD), RT (MD): have revisited critically the manuscript. AF (MD): conception and design of the manuscript.

**Competing interests**

The authors declare that they have no competing interests.

**Received:** 14 February 2012 **Accepted:** 26 March 2012

**Published:** 26 March 2012

**Table 8 Adherence to the GFD in children with T1D-CD**

| Reference | Country          | Prevalence (%) |
|-----------|------------------|----------------|
| Acenini et al. | United Kingdom | Partial         |
| Westman et al. | Australia        | 30             |
| Valerio et al. | Italy            | 59             |
| Saadah et al. | Australia        | 25             |

| Reference | Country          | Prevalence (%) |
|-----------|------------------|----------------|
| Acerini et al. | United Kingdom | Partial         |
| Westman et al. | Australia        | 30             |
| Valerio et al. | Italy            | 59             |
| Saadah et al. | Australia        | 25             |

**References**

1. Barker JM, et al. Clinical review: type 1 diabetes-associated autoimmunity: natural history, genetic associations and screening. J Clin Endocrinol Metab 2006, 91(0021-972X):1210-1217.
2. Smyth DJ, Plagnol V, Waker NM, Cooper JD, Downes K, Yang JH, Howson JM, Stevens H, McManus R, Wijmenga C, Heag GA, Dubois PC, Clayton DG, Hunt KA, Heel Van, Todd JA. Shared and distinct genetic variant in Type 1 diabetes and celiac disease. N Eng J Med 2008, 359(0028-4793):2837-2838.
3. Ide A, Eisenbarth GS: Genetic susceptibility in type 1 diabetes and its associated autoimmune disorders. Rev Endocr Metab Disord 2003, 4(3):245-253, 1389-9155.
4. Bao F, Yu L, Babu S, Wang T, Hoffenberg EJ, Revers M, Eisenbarth GS: One third of HLA DQ2 homozygous patients with type 1 diabetes express celiac disease associated transglutaminase autoantibodies. J Autoimmun 1999, 13:143-148, 0896-8411.
5. Cerruti F, Bruno G, Chiarelli F, Lorini R, Meschi F, Sacchetti C. Diabetes Study Group of the Italian Society of Pediatric Endocrinology and Diabetology. Younger age at onset and sex predict celiac disease in children and adolescents with type 1 diabetes: an Italian multicenter study. Diabetes Care 2004, 27:1294-1298.
6. Contreas G, Valletta E, Ulmi D, Cantoni S, Pinelli L. Screening of celiac disease in north Italian children with type 1 diabetes: limited usefulness of HLA-DQ typing. Acta Paediatr 2004, 93:628-632.
7. Sanchez-Albuisa I, Wolf J, Neu A, Geiger H, Waechter I, Stem M. Coeliac disease in children with type 1 diabetes mellitus: the effect of the gluten free diet. Diabet Med 2005, 22:1079-1082.
8. Araujo J, da Silva GA, de Melo FM. Serum prevalence of celiac disease in children and adolescents with type 1 diabetes mellitus. J Pediatr (Rio J) 2008, 82:210-214.
9. Goh C, Banejee K. Prevalence of celiac disease in children and adolescents with type 1 diabetes mellitus in a clinic based population. Postgrad Med J 2007, 83:132-136.
10. Larsson K, Carlson A, Cederwall E, Jonsson B, Neiderud J, Jonsson B, Lernmark A, Ivansson SA. Study Group: Annual screening detects celiac disease in children with type 1 diabetes. Pediatr Diabetes 2008, 9:354-358.
11. Karavanlaki K, Kakkaas K, Pascale L, Kefalas N, Konstantopoulos I, Petrou V, Kanarou M, Karayanni C. Screening for associated autoimmunity in children and adolescents with type 1 diabetes mellitus (T1DM). Horm Res 2009, 71:201-206.
12. Djunic Z, Stamenkovic H, Stankovic T, Miletovic B, Hankovic L, Cinc V. Celiac disease prevalence in children and adolescents with type 1 diabetes from Serbia. Pediatr Int 2010, 52:579-583.
13. Bhadada SK, Kochlar R, Bhansali A, Dutta U, Kumar PR, Poornachandra KS, Vaiphei K, Nain CK, Singh K. Prevalence and clinical profile of celiac disease in type 1 diabetes mellitus in north India. J Gastroenterol Hepatol 2011, 2:378-381.
14. Gabriel S, Mihela L, Angela B, Marana A, Doru D. Prevalence of IgA antitissue transglutaminase antibodies in children with type 1 diabetes mellitus. J Clin Lab Anal 2011, 25(3):156-161.
15. Kaspers S, Kordoumi O, Schoiber G, Grabert M, Hauffa BP, Holl RW, German Working Group for Pediatric Diabetology: Anthropometry, metabolic control, and thyroid autoimmunity in type 1 diabetes with celiac disease: A multicenter survey. J Pediatr 2004, 145(6):790-795, 0022-3476.
16. Cerruti F, Bruno G, Chiarelli F, Lorini R, Meschi F, Sacchetti C. Diabetes study group of the Italian Society of Pediatric Endocrinology and Diabetology. Younger age at onset and sex predict celiac disease in children and adolescents with type 1 diabetes: an Italian multicenter study. Diabetes Care 2004, 27(6):1294-1298, 0149-5992.
17. Valerio G, Mauiri L, Troncone R, Buono P, Lombardi F, Palmieri R, Tranzese A. Severe clinical onset of diabetes and increased prevalence of other autoimmune diseases in children with coeliac disease diagnosed before diabetes. Diabetologia 2002, 45(12):1719-1722, 0012-186X.
18. Pecceco M, Ventura A. Coeliac disease and insulin-dependent diabetes mellitus: a causal association? Acta Paediatr 1995, 84(12):1432-1433, 0803-5253.
19. Ventura A, Magazzù G, Greco L. Duration of exposure to gluten and risk for autoimmune disorders in patients with celiac disease. SGEP Study Group for Autoimmune Disorders in Celiac Disease. Gastroenterology 1999, 117(2):293-303, 0166-5085.
20. Ventura A, Neri E, Ughi C, Leopaldi A, Citta A, Not T. Gluten-dependent diabetes-related and thyroid-related autoantibodies in patients with celiac disease. J Pediatr 2000, 137(2):263-265, 0022-3476.
21. Viljamaa M, Kaukinen K, Huhtala H, Kyronpalo S, Rasmussen M, Collin P. Coeliac disease, autoimmune diseases and gluten exposure. Scand J Gastroenterol 2005, 40(4):437-443, 0366-5521.
22. Holmes GK. Coeliac disease and Type 1 diabetes mellitus: the case for screening. Diabet Med 2001, 18(3):169-177, 0743-3071.
23. Holmes GK. Potential and latent coeliac disease. Gut J Gastroenterol Hepatol 2001, 13(9):1057-1060, 0954-691X.
24. Paparo F, Petione E, Tosco A, Maglio M, Borrelli M, Salvati VM, Miele E, Greco L, Auricchio S, Troncone R. Clinical, HLA, and small bowel immunohistochemical features of children with positive serum
antiendomysium antibodies and architecturally normal small intestinal mucosa. Am J Gastroenterol 2005, 100(10):2294-2298, 0002-9270.

25. Troncone R, Greco L, Mayer M, Paparo F, Caputo N, Micillo M, Mugione P, Auriocco S. Latent and potential celiac disease. Acta Paediatr Suppl 1996, 421(10-14): 0809-2.525.

26. Franzese A, Iafusco D, Spadaro D, Cavaleri O, Prisco F, Auriocco R, Troncone R, Valerio G. The Study Group on Diabetes of Italian Society of Pediatric Endocrinology and Diabetology: Potential celiac disease in type 1 diabetes: A multicenter study. Diabetes Res Clin Pract 2011, 92(1):53-56, 0168-8227.

27. Peretti N, Bienvenu F, Bouvet C, Fabien N, Tixier F, Thivolet C, Levy E, Chatelain PG, Lachaux A, Nicollino M. The temporal relationship between the onset of type 1 diabetes and celiac disease: a study based on immunoglobulin A antitransglutaminase screening. Pediatrics 2004, 113: e418-e422.

28. Karavanaki K, Kakleas K, Paschali E, Kefelas N, Konstantopoulos I, Petrou V, Kanariou M, Karayannis C. Screening for associated autoimmunity in children and adolescents with type 1 diabetes mellitus (T1DM). Horm Res 2009, 71:201-206.

29. Hubsy S, Koletzko S, Korpay-Szabolc IR, et al. The ESPGHAN Working Group on Coeliac Disease Diagnosis. ESPGHAN Guidelines for the Diagnosis of Coeliac Disease in Children and Adolescents. Am Evidence-Based Approach. JPGN 2012, 54(1):136-160.

30. Collin P, Kaukinen K, Valimaki M, Salmi J. Endocrinological disorders and celiac disease. Endocr Rev 2002, 23(4):464-483, 0163-769X.

31. Freemark M, Levitsky LL. Screening for celiac disease in children with type 1 diabetes: two views of the controversy. Diabetes Care 2003, 26(6):1932-1939, 0149-5992.

32. Rubio-Tapia A, Kyle RA, Kaplan EL, Johnson DR, Page W, Erdtman F, Brantner TL, Kim WR, Phillips TK, Lahr BD, Zinsmeister AR, Melton LL, Murray JA. Increased prevalence and mortality in undiagnosed celiac disease. Gastroenterology 2009, 137(1):88-93, 0036-5521.

33. Hansen D, Brock-Jacobsen B, Lund E, Bjorn C, Hansen LP, Nielsen C, Fenger C, Lillevang ST, Hubsy S. Clinical benefit of a gluten-free diet in type 1 diabetic children with screening-detected celiac disease: a population-based screening study with 2 years’ follow-up. Diabetes Care 2006, 29(11):2452-2456, 0149-5992.

34. Sanchez-Albusa J, Wolf J, Neu A, Geiger H, Wascher I, Stern M. Celiac disease in children with Type 1 Diabetes mellitus: the effect of the gluten-free diet. Diabet Med 2005, 22(8):1079-1082, 0742-5701.

35. Artz E, Warren-Ulanch J, Becker D, Greenspan S, Freemark M. Seropositivity to celiac antigens in asymptomatic children with type 1 diabetes mellitus: association with weight, height, and bone mineralization. Pediatr Diabetes 2008, 9(4):277-284, 1399-543X.

36. Rami B, Sumnik Z, Schober E, Waldhor T, Battelino T, Bratanic N, Kurti K, Mayer M, Sblattero D, Troncone R, Valerio G, Bone involvement in clusters of autoimmune diseases. Eur J Endocrinol 2005, 153:87-98.

37. Franzese A, Valerio G, Spadaro R, Iafusco D, Lombardi F, Del Puente A, Esposito A, et al. The influence of gluten free diet on quantitative ultrasound of proximal phalanges in children and adolescents with Type 1 Diabetes mellitus and celiac disease. Bone 2008, 43:322-326.

38. Foster-Powell Kaye, Susanna HA. International table of glycemic index and glycemic load values. Am J Clin Nutr 2002, 76(3):55-56.

39. Parker SC, Dornhost A, Frost GG. The glycaemic index of a range of gluten free foods. Diabetes Medicine 2000, 17:657-660.

40. Bent C, Riso P, Monti L, Pornini M. In vitro starch digestibility and in vivo glucose response of gluten free foods and their gluten counterparts. Eur J Nutr 2004, 43:198-204.

41. Kupper C. Dietary guidelines and implementation for celiac disease. Gastroenterology 2005, 128:S121-S127.

42. Erichelli S, Esposito O, Di Mase R, Camarca ME, Natale C, Limongelli MG, Marano C, Corizzo A, Lombardo M, Strisciuglio P, Greco L. Celiac disease: predictors of compliance with a gluten-free diet in adolescents and young adults. J Pediatr Gastroenterol Nutr 2010, 50(1):54-60.

43. Francese A, Valerio G, Spagnuolo MI. Management of diabetes in childhood: are children small adults? J Pediatr Gastroenterol Nutr 2010, 50(3):293-305.

44. Rashid M, Cranney A, Zarkadas M, Graham ID, Switzer C, Mulvey M, Warren RE, Burrows V, Butzner JD. Celiac disease: evaluation of the diagnosis and dietary compliance in Canadian children. Pediatrics 2005, 116(6):e754-e759.

45. Van Koppens EJ, Schweizer JJ, Ciszmadia CG, Krom Y, Hylkema HB, van Geel AM, Koopman HM, Verbov-Vanhoick SP, Mearin ML. Long-term health and quality-of-life consequences of mass screening for childhood celiac disease: a 10-year follow-up study. Pediatrics 2009, 123(4): e582-e588.

46. Kosteren MM, Koopman HM, Schalekamp G, Mearin ML. Health-related quality of life in children with celiac disease. J Pediatr, 2001, 138(4):593-595.

47. Wagner N, Berger G, Sinnreich U, Grylls V, Schober E, Huber WD, Karvauz A. Quality of life in adolescents with treated coeliac disease: influence of compliance and age at diagnosis. J Pediatr Gastroenterol Nutr 2008, 47(5):555-561.

48. Rubin RR, Peyrot M. Quality of life and diabetes. Diabetes Metab Rev 2001, 17:205-218.

49. Sut S, Marcon M, Assor E, Daneman D, Mahmud FH. Quality of life in children with diabetes and celiac disease: minimal impact of the ‘double diagnosis’. Pediatr Diabetes 2011.